Akebia Therapeutics, Inc.
DE ˙ DB ˙ US00972D1054
0,83 € ↓ -0,02 (-2,69%)
2026-06-03
DEL PRIS
SecurityDE:AX9 / Akebia Therapeutics, Inc.
InstitutionPrudential Financial Inc
Latest Disclosed Ownership40,274 shares
Latest Disclosed Value $ 55,981
Prudential Financial Inc reports 21.83% decrease in ownership of AX9 / Akebia Therapeutics, Inc.

On May 13, 2026 - Prudential Financial Inc filed a 13F-HR form disclosing ownership of 40,274 shares of Akebia Therapeutics, Inc. (DE:AX9) valued at $45,953 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 51,524 shares of Akebia Therapeutics, Inc.. This represents a change in shares of -21.83% during the quarter. The current value of the position is $33,460 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F AKEBIA THREAPEUTICS COM 00972D105 40,274 -11,250 -21.83 56 -32.93 0.0001
2026-02-13 2025-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 51,524 -229,034 -81.64 83 -89.28 0.0001
2025-11-13 2025-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 280,558 -134,585 -32.42 766 -49.37 0.0009
2025-08-12 2025-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 415,143 350,504 542.25 1,511 1,118.55 0.0020
2025-05-13 2025-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 64,639 170 0.26 124 1.64 0.0002
2025-02-11 2024-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 64,469 0 0.00 122 43.53 0.0002
2024-11-14 2024-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 64,469 50,200 351.81 85 507.14 0.0001
2024-08-13 2024-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 14,269 -23,840 -62.56 15 -79.71 0.0000
2024-05-14 2024-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 38,109 16,000 72.37 70 155.56 0.0001
2024-02-13 2023-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 22,109 -25,400 -53.46 27 -50.00 0.0000
2023-11-13 2023-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 47,509 0 0.00 54 25.58 0.0001
2023-08-11 2023-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 47,509 47,509 43 0.0001
2022-08-15 2022-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 0 -249,912 -100.00 0 -100.00
2022-05-13 2022-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 249,912 -381,000 -60.39 177 -87.59 0.0002
2022-02-14 2021-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 630,912 -452,993 -41.79 1,426 -54.31 0.0018
2021-11-15 2021-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,083,905 1,062,864 5,051.39 3,121 3,801.25 0.0044
2021-08-16 2021-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 21,041 2,655 14.44 80 29.03 0.0001
2021-05-12 2021-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 18,386 60 0.33 62 21.57 0.0001
2021-08-16 2020-12-31 13F/A-1 AKEBIA THERAPEUTICS COM 0002 00972D105 18,326 0 0.00 51 10.87 0.0001
2021-02-16 2020-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 18,326 0 51 0.0001
2020-11-16 2020-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 18,326 6,659 57.08 46 -70.89 0.0001
2020-08-12 2020-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 11,667 11,667 158 0.0003
2020-05-12 2020-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -12,760 -100.00 0 -100.00
2020-02-11 2019-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 12,760 1,600 14.34 81 84.09 0.0001
2019-11-13 2019-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 11,160 1,143 11.41 44 -8.33 0.0001
2019-08-08 2019-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 10,017 -12,540 -55.59 48 -74.05 0.0001
2019-05-15 2019-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 22,557 -2,476 -9.89 185 34.06 0.0003
2019-02-07 2018-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 25,033 6,673 36.35 138 -14.81 0.0002
2018-11-07 2018-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 18,360 -410 -2.18 162 -13.37 0.0002
2018-08-13 2018-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 18,770 18,770 187 0.0003
2018-02-13 2017-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -49,360 -100.00 0 -100.00
2017-11-02 2017-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 49,360 49,360 971 0.0016
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.